IV vs. shot vedolizumab for IBD with remote check-ins
Part of Digestive system clinical trials.
This study compares two ways of taking the IBD medicine vedolizumab (injecting under the skin versus through an IV line). You'll use a smartphone app to report your symptoms, so you can participate from home and help doctors learn which option works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of inflammatory bowel disease (IBD) like Crohn's or ulcerative colitis.
- You must be starting treatment with vedolizumab (Entyvio).
- You need a smartphone (iPhone 7 or newer, or Android from 2012 or later) with internet or Wi-Fi.
- You should be able to read and speak English or Spanish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
This study tests whether a weekly/regular skin injection version of vedolizumab can help adults with moderate to severe ulcerative colitis or Crohn’s disease who did not fully respond to other treatments or TNF blockers. It may help by moving you from an intravenous (IV) infusion to a self/clinic injection option.
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
This trial tests if regular video check-ins via phone or computer can help people with IBD stick to their medications and feel better emotionally. You would use a messaging app and video calls to stay in touch with your care team from home.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This study tests whether measuring drug levels in the blood can help doctors find the best dose of vedolizumab (Entyvio) or ustekinumab (Stelara) for people with ulcerative colitis or Crohn's disease. It aims to improve control of these conditions while keeping treatment safe.
Hear when a new Crohn's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.